SAbDab: The Structural Antibody Database

Search results

89 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)

Therapeutic	Format	Highest Clinical Trial (Jan '20)	Est. Status (Jan '20)	Target	Year Proposed	100% SI Struc.	99% SI Struc.	95-98% SI Struc.
acapatamab	Bispecific scFv	Phase-I/II	Discontinued	FOLH1/GCPII/PSMA;CD3E	2020	no;no	no;no	no;no
acasunlimab	Bispecific mAb	Phase-I/II	Active	PDL1/CD274;TNFRSF9/CD137/4-1BB	2020	no;no	no;no	no;no
alnuctamab	Bispecific mAb with Domain Crossover	Phase-I	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
alomfilimab	Whole mAb	Phase-II	Active	ICOS/CD278	2020	YES	no	no
amlitelimab	Whole mAb	Phase-II	Active	TNFSF4/CD134/CD252/OX40L	2020	no	no	no
anbenitamab	Bispecific mAb	Phase-II/III	Active	ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV)	2020	no;YES	no;YES	no;YES
ansuvimab	Whole mAb	Approved	Active	Zaire Ebolavirus Glycoprotein	2020	no	YES	no
apitegromab	Whole mAb	Phase-III	Active	pro-MSTN/pro-GDF8	2020	no	no	YES
atibuclimab	Whole mAb	Phase-II	Active	CD14	2020	no	no	no
bamlanivimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike	2020	YES	no	no
bapotulimab	Whole mAb	Phase-I	Active	ILDR2	2020	no	no	no
barecetamab	Whole mAb	Phase-I	Discontinued	ERBB3/HER3	2020	YES	no	no
bavunalimab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	LAG3/CD223;CTLA4/CD152	2020	no;no	no;no	no;no
bentracimab	Whole mAb	Phase-III	Active	AR-C124910XX	2020	YES	no	YES
botensilimab	Whole mAb	Phase-II	Active	CTLA4/CD152	2020	no	no	no
cadonilimab	Bispecific Mixed mAb and scFv	Approved	Active	PDCD1/CD279/PD1;CTLA4/CD152	2020	no;no	no;no	no;no
cilgavimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
coprelotamab	Whole mAb	Phase-III	Active	ERBB2/CD340/HER2	2020	YES	YES	YES
dafsolimab	Whole mAb	Phase-III	Active	CD3E	2020	no	no	no
daxdilimab	Whole mAb	Phase-II	Active	LILRA4/CD85g	2020	no	no	no
depemokimab	Whole mAb	Phase-III	Active	IL5	2020	no	no	no
divozilimab	Whole mAb	Phase-III	Active	MS4A1/CD20	2020	no	no	no
domvanalimab	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2020	no	no	no
ebdarokimab	Whole mAb	Phase-III	Active	IL12B/CLMFp40	2020	no	no	no
ebronucimab	Whole mAb	Phase-III	Active	PCSK9	2020	no	no	no
eluvixtamab	Bispecific scFv	Phase-I	Discontinued	SIGLEC3/CD33/p67;CD3E	2020	no;no	no;no	no;no
emerfetamab	Bispecific scFv	Phase-I	Active	SIGLEC3/CD33/p67;CD3E	2020	no;no	no;no	no;no
enibarcimab	Whole mAb	Phase-II	Active	ADM	2020	no	no	no
eramkafusp	Whole mAb Fusion	Phase-I	Discontinued	MS4A1/CD20	2020	YES	YES	no
erfonrilimab	Bispecific Single Domains (VH-VH'-CH)	Phase-III	Active	PDL1/CD274;CTLA4/CD152	2020	no;YES	no;no	no;no
etesevimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
etevritamab	Bispecific scFv	Phase-I	Discontinued	EGFR/ERBB1/HER1;CD3E	2020	no;no	no;no	no;no
finotonlimab	Whole mAb	Phase-III	Active	PDCD1/CD279/PD1	2020	no	no	no
garivulimab	Whole mAb	Phase-I/II	Active	PDL1/CD274	2020	no	no	no
geptanolimab	Whole mAb	Preregistration	Active	PDCD1/CD279/PD1	2020	no	no	no
grisnilimab	Whole mAb	Phase-I/II	Active	CD7	2020	no	no	no
idactamab	Whole mAb	Phase-I	Active	SLC1A5	2020	no	no	no
imsidolimab	Whole mAb	Phase-III	Active	IL36R	2020	no	no	no
izuralimab	Bispecific Mixed mAb and scFv	Phase-II	Active	ICOS/CD278;PDCD1/CD279/PD1	2020	no;no	no;no	no;no
latozinemab	Whole mAb	Phase-III	Active	SORT1	2020	no	no	no
lemzoparlimab	Whole mAb	Phase-III	Active	IAP/CD47	2020	no	no	no
letaplimab	Whole mAb	Phase-I/II	Active	IAP/CD47	2020	no	no	no
licaminlimab	scFv	Phase-II	Active	TNF/TNFA	2020	no	no	no
lirentelimab	Whole mAb	Phase-III	Active	SIGLEC8/SAF2	2020	no	YES	no
lonigutamab	Whole mAb	Phase-I/II	Active	IGF1R/CD221	2020	no	no	no
lusvertikimab	Whole mAb	Phase-II	Active	IL7R/CD127	2020	no	no	no
masavibart	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
melrilimab	Whole mAb	Phase-II	Discontinued	IL1RL1/ST2	2020	no	no	no
mibavademab	Whole mAb	Phase-II	Active	LEPR/CD295/OBR	2020	no	no	no
mipasetamab	Whole mAb	Phase-I	Active	AXL/UFO	2020	no	no	no
nadecnemab	Whole mAb	Phase-II	Active	GFRA3	2020	no	no	no
nepuvibart	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
nivatrotamab	Bispecific Mixed mAb and scFv	Phase-I/II	Active	GD2;CD3E	2020	no;no	no;no	no;no
obrindatamab	Bispecific scFv with Domain Crossover	Phase-I	Discontinued	B7H3/CD276;CD3E	2020	no;no	no;no	no;no
ociperlimab	Whole mAb	Phase-III	Active	TIGIT/WUCAM/VSTM3	2020	no	no	no
omodenbamab	Whole mAb	Phase-I/II	Active	Staphylococcus aureus Protein A	2020	no	no	no
ordesekimab	Whole mAb	Phase-II	Active	IL15	2020	no	no	no
pacanalotamab	Bispecific scFv	Phase-I	Active	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
pavurutamab	Bispecific scFv	Phase-I	Discontinued	TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E	2020	no;no	no;no	no;no
pelgifatamab	Whole mAb ADC	Phase-I	Active	FOLH1/GCPII/PSMA	2020	no	no	no
penpulimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
pimivalimab	Whole mAb	Phase-II	Active	PDCD1/CD279/PD1	2020	no	no	no
plonmarlimab	Whole mAb	Phase-II/III	Active	CSF2	2020	no	no	no
ponsegromab	Whole mAb	Phase-I	Discontinued	GDF15/MIC1	2020	no	no	no
pucotenlimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no
recaticimab	Whole mAb	Phase-III	Active	PCSK9	2020	no	no	no
regdanvimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
retlirafusp	Whole mAb Fusion	Phase-III	Active	PDL1/CD274	2020	no	no	no
runimotamab	Bispecific mAb	Phase-I	Active	ERBB2/CD340/HER2;CD3E	2020	YES;no	YES;no	YES;no
sibeprenlimab	Whole mAb	Phase-III	Active	TNFSF13/CD256/APRIL	2020	no	no	no
sotigalimab	Whole mAb	Phase-II	Active	TNFRSF5/CD40	2020	no	no	no
sotrovimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	no	YES;YES	no
sudubrilimab	Whole mAb	TBC	Active	PDL1/CD274	2020	no	no	YES
surzebiclimab	Whole mAb	Phase-II	Active	HAVCR2/TIM3	2020	no	no	no
tarlatamab	Bispecific scFv	Phase-III	Active	DLL3;CD3E	2020	no;no	no;no	no;no
tirnovetmab	Whole mAb (Canine)	Unknown	Active	IL31 (Canine)	2020	no	no	no
tixagevimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	YES	YES
torudokimab	Whole mAb	Phase-II	Active	IL33	2020	no	no	no
tozorakimab	Whole mAb	Phase-III	Active	IL33	2020	no	no	no
tusamitamab	Whole mAb	Phase-III	Active	CEACAM5/CD66e	2020	no	no	no
uliledlimab	Whole mAb	Phase-II	Active	NT5E/CD73	2020	no	no	no
unasnemab	Whole mAb	Phase-II	Active	RGMA	2020	no	no	no
vixarelimab	Whole mAb	Phase-II	Active	OSMR	2020	no	no	no
vixtimotamab	Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)	Phase-I	Discontinued	CD3E;SIGLEC3/CD33/p67	2020	no;no	no;no	no;no
vudalimab	Bispecific Mixed mAb and scFv	Phase-II	Active	CTLA4/CD152;PDCD1/CD279/PD1	2020	no;no	no;no	YES;no
zansecimab	Whole mAb	Phase-II	Discontinued	ANGPT2	2020	no	no	no
zeluvalimab	Whole mAb	Phase-I/II	Active	PDCD1/CD279/PD1	2020	no	no	no
zilovertamab	Whole mAb	Phase-II	Active	ROR1	2020	no	no	no
zimberelimab	Whole mAb	Approved	Active	PDCD1/CD279/PD1	2020	no	no	no

Search again

> About

This database is described in the following paper: Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):gkz827.

Antibody- and Nanobody-derived therapeutics with known sequences, and their structural coverage in the PDB.

Use the 'Get all therapeutics' tab to get a list of all immunotherapeutics.

Search by name: Find a specific entry using its INN -mab or -fusp name.

Search by attribute: Find a subset of immunotherapeutics with particular attributes. Choose from format, target, highest clinical trial reached, development status, year INN proposed, or structural coverage (or any combination).

Search by sequence: Find therapeutics near to your query sequence over any Chothia-defined region of the heavy and/or light chain variable domain sequence.

For more help, see the About page.

If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

>   Get all immunotherapeutics

>   Search for a specific therapeutic

Please type a therapeutic INN name:

>   Search therapeutics by attribute

Therapeutic format:

Year INN Proposed:

Highest Clinical Trial:

Developmental Status:

Target:

Restrict to Known Structures:

>   Search for therapeutics by sequence similarity

Heavy chain sequence:

load example

Light chain sequence:

load example

Max No. of Therapeutics to be returned:

Minimum sequence identity:

Region to consider:

>   Downloads

Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.

Download a spreadsheet of all therapeutic sequences/structures (last list - PL128): xlsx / csv

If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

Thera-SAbDab

(Therapeutic Structural Antibody Database)

Search results

Search again